Interferons Transcriptionally Up-Regulate MLKL Expression in Cancer Cells.

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Interferons (IFNs) are crucial for anti-tumor immunity, mediating their effects through IFN-stimulated genes (ISGs).
• Understanding the regulation and function of ISGs is vital for developing novel cancer therapies.
• Apoptosis resistance remains a significant challenge in cancer treatment.

Purpose of the Study:

• To identify novel IFN-stimulated genes (ISGs) involved in the tumor immune response.
• To investigate the role of mixed-lineage kinase domain-like pseudokinase (MLKL) as an ISG.
• To explore the therapeutic potential of IFN-induced MLKL in overcoming cancer cell apoptosis resistance.

Main Methods:

• MLKL expression was analyzed in various cancer cell lines following treatment with type I and type II IFNs.
• Transcriptional regulation of MLKL by IFNγ was assessed using Actinomycin D chase experiments.
• The role of transcription factors IRF1 and STAT1 in IFNγ-mediated MLKL induction was evaluated through knockdown and knockout studies.

Main Results:

• Mixed-lineage kinase domain-like pseudokinase (MLKL) was identified as an IFN-stimulated gene (ISG) in multiple cancer cell lines.
• Both type I and type II IFNs increased MLKL expression, indicating a general response to IFN signaling.
• IFNγ was shown to transcriptionally regulate MLKL, with IRF1 and STAT1 playing key roles in this induction.
• IFNγ-induced MLKL up-regulation was observed to sensitize cancer cells to necroptotic cell death.

Conclusions:

• MLKL is a novel ISG transcriptionally regulated by IFNγ.
• IFNγ-induced MLKL sensitizes cancer cells to necroptosis, offering a strategy to overcome apoptosis resistance.
• Targeting MLKL induction by IFNs may represent a promising therapeutic approach for cancer treatment.